TGFB1 and medulloblastoma: Therefore, we propose the same novel immunotherapeutic approach for medulloblastoma, consisting of TGF-β-resistant cord blood-derived NK cells as an “off the shelf” cell therapeutic, and specifically propose to evaluate its application as a treatment to overcome the TGF-β-rich environment in medulloblastoma.